Imaging of Arthropathy in Boys With Hemophilia in China

Hemophilia Clinical Trial

Official title: Radiogenomics: Personalized Imaging of Arthropathy in Boys With Hemophilia in China

Status Completed

Clinical Trial Summary

Hemophilia is a genetic condition characterized by marked phenotypic heterogeneity. Bleeding into a joint is the single most important risk factor for the development of hemophilic arthropathy (HA). It is thought that clinical and imaging manifestations of HA are at least partially attributable to genetic polymorphisms unrelated to the hemophilia genotype. Identifying and characterizing biologic factors that could explain differences in susceptibility to joint degeneration of patients with hemophilia would help stratify patients according to the risk of degeneration of their joints and develop personalized therapeutic and prophylactic strategies. This study is conducted in China.

Clinical Trial Description

This will be a 3-year prospective cohort study conducted in a single centre (Beijing Children's Hospital, BCH, China) with a 2-year follow-up of patients Index joints (ankles, elbows and knees) of young Chinese boys with hemophilia A will be evaluated as follows: physical examination every 6 months using the Hemophilia Joint Health Score [HJHS], ultrasound imaging (gray-scale and color Doppler ultrasound [US]), and by laboratory (serum) at baseline, at 6, and 24 months. Magnetic resonance imaging (MRI) scans of index joints will be obtained at baseline, and 24 months. Features that will be captured either quantitatively or semantically in the imaging scans will be aggregated to generate "imaging phenotypes" which will be associated with clusters of co-expressed genes (metagenes) and clinical data. ;

Related Conditions & MeSH terms

• Hemophilia
• Hemophilia A
• Joint Diseases

• NCT number: NCT03914716
• Study type: Interventional
• Source: The Hospital for Sick Children
• Status: Completed
• Phase: N/A
• Start date: March 21, 2018
• Completion date: November 30, 2023